NCT06410040View on ClinicalTrials.gov

A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis

Active, not recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

August 20, 2023

Primary Completion Date

March 31, 2024

Study Completion Date

June 30, 2024

Conditions

ALK-positive Non-small Cell Lung CancerBrain MetastasesMeningeal Metastasis

Interventions

DRUG

Lorlatinib

lolatinib 100mg qd po

Trial Locations (1)

610000

Sichuan cancer hospital, Chengdu

All Listed Sponsors

lead

Sichuan Cancer Hospital and Research Institute

OTHER

NCT06410040 - A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis | Biotech Hunter | Biotech Hunter